ArticleIntensive care medicine2007
Pharmacokinetic/pharmacodynamic analysis of vancomycin in ICU patients.
Article in Intensive care medicine, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 1 synthesis or guideline pooled it, 167 citations in OpenAlex.
- Optimal dosing of antibiotics in critically ill patients by using continuous/extended infusions: a systematic review and meta-analysis.Critical care (London, England) · 2013Pooled it
- External Validation of a Pharmacokinetic Model Developed for Vancomycin Administration via Target-Controlled Infusion.Drug design, development and therapy · 2025Trial
- The pharmacokinetics of vancomycin in patients with severe acute pancreatitis.European journal of clinical pharmacology · 2016Trial
- Population pharmacokinetics of vancomycin in Thai patients.TheScientificWorldJournal · 2012Trial
- Population Pharmacokinetics of Vancomycin in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy: Influence of Adsorptive Membranes.Clinical and translational science · 2026Article
- Population Pharmacokinetics and Dose Optimization of Vancomycin in Adult Cancer Patients.Drug design, development and therapy · 2026Article
- Population pharmacokinetics of vancomycin in non-extremely preterm neonates based on real-world studies: influence of daily fluid input and diuretics.Microbiology spectrum · 2025Article
- The Protective Effect of Omeprazole on Vancomycin Cytotoxicity in HK-2 Cells and Renal Injury in Rats.BioMed research international · 2025Article
- New advances in management and treatment of cardiac implantable electronic devices infections.Infection · 2024Review
- Factors Affecting Vancomycin Trough Concentration; a Population Pharmacokinetic Model in Non-Critical Care Saudi Patients.Drug design, development and therapy · 2024Article
- Pharmacokinetics in Critically Ill Children with Acute Kidney Injury.Paediatric drugs · 2023Review
- LCFrontiers in pharmacology · 2023Article
- Daptomycin and linezolid for severe methicillin-resistantWorld journal of clinical cases · 2022Article
- Pharmacokinetic/Pharmacodynamic Target Attainment of Vancomycin, at Three Reported Infusion Modes, for Methicillin-ResistantFrontiers in cellular and infection microbiology · 2022Article
- Population pharmacokinetic model of vancomycin in postoperative neurosurgical patients.Frontiers in pharmacology · 2022Article
- Exploring population pharmacokinetic models in patients treated with vancomycin during continuous venovenous haemodiafiltration (CVVHDF).Critical care (London, England) · 2021Article
- Population Pharmacokinetic Modeling and Dose Optimization of Vancomycin in Chinese Patients with Augmented Renal Clearance.Antibiotics (Basel, Switzerland) · 2021Article
- Population Pharmacokinetics and Dosing Simulation of Vancomycin Administered by Continuous Injection in Critically Ill Patient.Antibiotics (Basel, Switzerland) · 2021Article
- Establishment of a population pharmacokinetics model of vancomycin in 94 infants with septicemia and its application in individualized therapy.BMC pharmacology & toxicology · 2021Article
- Population pharmacokinetic modeling and clinical application of vancomycin in Chinese patients hospitalized in intensive care units.Scientific reports · 2021Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsTo identify the variables affecting vancomycin pharmacokinetics in medical ICU patients and to evaluate the potential efficacy of dosage schedules by PK/PD analysis.
designA retrospective pharmacokinetic analysis of serum levels obtained in routine vancomycin monitoring was performed.
settingA 12-bed general ICU of a university teaching hospital. PATIENTS: Forty-six vancomycin-treated ICU patients fitting the following criteria: over 18 years old; more than three concentration data per patient; absence of renal replacement support, cardiac surgery and neoplastic disorders.
interventionsClinical information was collected from the patients' medical records. Details of vancomycin therapy, dosage and blood sampling times were obtained from pharmacokinetic reports. Population analysis were made by the standard two-stage approach. MEASUREMENTS AND MAIN
resultsVancomycin clearance and distribution volume were estimated individually assuming a one-compartment pharmacokinetic model. PK/PD analysis was performed by Monte Carlo simulation. In the ICU patients, higher Vd (nearly twice the quoted value of 0.72 l/kg) and different vancomycin clearance-creatinine clearance relationship were found. Renal function, the APACHE score, age and serum albumin accounted for more than 65% of drug clearance variability. Vancomycin standard dosages led to a 33% risk of not achieving the recommended AUC(24h)/MIC breakpoint for Staphylococcus aureus.
conclusionsThe population kinetics and PK/PD analyses based on Monte Carlo simulation procedures offer an excellent tool for selecting the therapeutic option with the highest probability of clinical success in ICU patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.